

Letters to the Editor

Detection of Yellow Fever 17D Genome in Urine[▽]

Yellow fever (YF) remains an important public health problem in regions where the disease is endemic, with a dramatic upsurge in the number of cases in recent years. So far, extensive YF epizootics occurred in South America in 2008, and during the past year YF outbreaks arose in Cameroon, Democratic Republic of Congo, Guinea, Côte d'Ivoire, Central African Republic, and Liberia (<http://www.who.int/>). Highly effective, live attenuated YF vaccines against the disease have been available for decades and have had a major impact on the incidence of the disease (17).

The clinical diagnosis of isolated cases of YF or identification of vaccine-associated adverse events (YFVAE) is particularly difficult because the symptoms are quite similar to those of many other diseases (20). Laboratory confirmation is therefore essential and relies on the detection of YF-specific IgM or a 4-fold or greater rise in serum IgG levels (in the absence of recent YF vaccination), isolation of yellow fever virus (YFV), positive postmortem liver histopathology, detection of YF antigen in tissues by immunohistochemistry, or detection of YFV RNA by PCR, which provides the earliest diagnosis possible. Samples recommended for diagnostics are blood, serum, cerebrospinal fluid (CSF), peritoneal or pleural fluid, and liver biopsy specimens (1, 20). However, biopsies and invasive techniques must be avoided or practiced with extreme caution due to the risk of bleeding complications (5).

To explore the suitability of noninvasive samples for the diagnosis of acute YF infections or YFVAE, we have collected urine samples ($n = 129$) from YF-17D vaccinees (day 0 to day 28), comprising sequential samples from 13 healthy primary vaccinees, 1 revaccinated individual, and 18 individuals with suspected YFVAE detected during mass-vaccination campaigns in Liberia and Cameroon. Urine samples from suspected YFVAE were collected at only one time point, when patients demanded medical assistance. Ten preimmune urine samples were also included in the study presented here.

RNA was extracted from 1 ml of freshly thawed urine by using the inRICHMENT virus reagent (Analytik Jena AG, Jena, Germany), followed by the QIAmp viral RNA minikit (Qiagen, CA) according to the manufacturer's instructions. Specific YF-17D genome was detected by quantitative real-time reverse transcription (RT)-PCR performed as described previously (3).

In our set of urine samples, 18 of 129 samples yielded positive amplification of the YF-17D genome, while all preimmune samples were negative. Among the healthy YF-17D vaccinees, four exhibited the presence of YFV RNA in their urine (28.6%), including three first-time vaccinees and the revaccinated one. The YF-17D genome was detected in the urine of these individuals in an intermittent mode, with more than one

consecutive day yielding positive amplification. From our results, it seems that a first excretion of YF-17D occurs in the first days after vaccination, and a second viral shedding (days 4 to 7) might happen, probably reflecting the viral replication in the vaccinees (Fig. 1).

Among suspected YFVAE patients, YF-17D genome was detected in 8 of 18 patients (44.4%) at different time points. Paired sera from these patients did not yield a positive amplification of YFV-17D genome. Remarkably, we found the presence of viral genome 20, 24, and 25 days after vaccination in the suspected YFVAE patients (Fig. 1). We can only hypothesize whether the presence of viral genome in urine at this time was a response to the prolonged replication of the virus in the patients affected or to a persistent viral shedding of the vaccine virus which may occur in some individuals without further pathological significance.

The average viral load detected in positive samples was $8.8 \pm E02$ genome equivalents (GE)/ml, ranging between 30 and 70 GE/ml ($n = 4$ samples) to 10^4 GE/ml ($n = 1$ sample), without any significant difference regarding the day of sample collection.

It has been reported that a low-level transient viremia is detectable in YF-17D vaccinees 4 to 6 days after vaccination and that this viremia does not exceed $2.3 \log_{10}$ PFU/ml or $2.23 \log_{10}$ copies/ml (12, 16, 19). However, higher levels have been reported in wild-type infections (2, 14) and severe YFVAE (4, 7, 13). The results presented are in agreement with these observations and deserve being thoroughly studied. A large-scale study to determine the features of YFV-17D shedding in urine and the correlation with viremia levels is ongoing. It would be highly desirable to explore the presence of YFV genome in wild-type cases, as we would then be able to anticipate that YF genome could be present in the urine of the patients during the course of the disease, providing a feature that could be extremely useful for diagnosis and identification of clinical cases.

The presence of viral RNA or antigens in urine has been demonstrated for other relevant flaviviruses causing human infections, such as West Nile virus (18), dengue virus (10, 15), Japanese encephalitis virus (9), or St. Louis encephalitis virus (8). This work is the first report of YF-17D genome detection in urine of vaccinees. The finding could be related to YFV replication, which may occur in the kidney (6, 11), and provides the opportunity for further research regarding YF and YF-17D pathogenesis and organ tropism. Moreover, the data reported have relevance for diagnostic purposes, since urine samples are very easy to collect, even from cases with hemorrhagic alterations or from newborns, without the need of invasive methods or trained personnel. Moreover, its use would be of great




FIG. 1. Detection of YF-17D genome in urine of healthy vaccinees (upper graph) or vaccinees with suspected adverse events (lower graph). Black bars represent positive samples; dotted bars represent negative samples. The black line indicates the percentage of positive samples from the total number of samples assayed at this time point. *, percentages could be biased by the small number of samples.

interest under field conditions such as suspected outbreaks or mass-vaccination campaigns.

REFERENCES

1. Anonymous. 2010. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm. Rep.* **59**:1–27.
2. Bae, H. G., et al. 2005. Analysis of two imported cases of yellow fever infection from Ivory Coast and the Gambia to Germany and Belgium. *J. Clin. Virol.* **33**:274–280.
3. Bae, H. G., A. Nitsche, A. Teichmann, S. S. Biel, and M. Niedrig. 2003. Detection of yellow fever virus: a comparison of quantitative real-time PCR and plaque assay. *J. Virol. Methods* **110**:185–191.
4. Belsher, J. L., et al. 2007. Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease. *Vaccine* **25**:8480–8485.
5. CDC. 11 July 2007, posting date. Special testing for selected patients with severe adverse events potentially related to yellow fever vaccination. Centers for Disease Control and Prevention, 1600 Clifton Rd., Atlanta, GA. <http://www.cdc.gov/ncidod/YellowFever/vaccine/special-testing.htm>.
6. De Brito, T., et al. 1992. Human fatal yellow fever. Immunohistochemical detection of viral antigens in the liver, kidney and heart. *Pathol. Res. Pract.* **188**:177–181.
7. Doblas, A., et al. 2006. Yellow fever vaccine-associated viscerotropic disease and death in Spain. *J. Clin. Virol.* **36**:156–158.
8. Luby, J. P., F. K. Murphy, J. N. Gilliam, C. Y. Kang, and R. Frank. 1980. Antigenuria in St. Louis encephalitis. *Am. J. Trop. Med. Hyg.* **29**:265–268.
9. Mathur, A., N. Khanna, R. Kulshreshtha, S. C. Maitra, and U. C. Chaturvedi. 1995. Viruria during acute Japanese encephalitis virus infection. *Int. J. Exp. Pathol.* **76**:103–109.
10. Mizuno, Y., et al. 2007. Confirmation of dengue virus infection by detection of dengue virus type 1 genome in urine and saliva but not in plasma. *Trans. R. Soc. Trop. Med. Hyg.* **101**:738–739.
11. Monath, T. P. 2001. Yellow fever: an update. *Lancet Infect. Dis.* **1**:11–20.
12. Monath, T. P., et al. 2003. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. *J. Infect. Dis.* **188**:1213–1230.
13. Munoz, J., et al. 2008. Yellow fever-associated viscerotropic disease in Barcelona, Spain. *J. Travel Med.* **15**:202–205.
14. Nassar Eda, S., et al. 1995. Jungle yellow fever: clinical and laboratorial studies emphasizing viremia on a human case. *Rev. Inst. Med. Trop. Sao Paulo* **37**:337–341.
15. Poloni, T. R., et al. 2010. Detection of dengue virus in saliva and urine by real time RT-PCR. *Virol. J.* **7**:22.
16. Reinhardt, B., R. Jaspert, M. Niedrig, C. Kostner, and J. L'Age-Stehr. 1998. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. *J. Med. Virol.* **56**:159–167.

17. **Staples, J. E., and T. P. Monath.** 2008. Yellow fever: 100 years of discovery. *JAMA* **300**:960–962.
18. **Tonry, J. H., et al.** 2005. West Nile virus detection in urine. *Emerg. Infect. Dis.* **11**:1294–1296.
19. **Trindade, G. F., et al.** 2008. Limited replication of yellow fever 17DD and 17D-Dengue recombinant viruses in rhesus monkeys. *An. Acad. Bras. Cienc.* **80**:311–321.
20. **WHO Media Centre.** 2009. Yellow fever fact sheet no. 10. World Health Organization, Geneva, Switzerland.

Cristina Domingo*

*Robert Koch Institut
Berlin, Germany*

Sergio Yactayo

*World Health Organization (WHO)
Epidemic Readiness and Intervention (ERI) Global Alert and
Response (HSE/GAR)
Geneva, Switzerland*

Edinam Agbenu

*Université de Lomé
Faculté Mixte de Médecine et de Pharmacie (FMMP-UL)
Lomé, Togo*

Maurice Demanou

*Centre Pasteur du Cameroun (CPC)
Yaoundé, Cameroon*

Axel R. Schulz

*Regenerative Immunology and Aging
Berlin-Brandenburg Center for Regenerative Therapies
Berlin, Germany*

Katjana Daskalow

*AJ Innuscreen
Berlin, Germany*

Matthias Niedrig

*Robert Koch Institut
Berlin, Germany*

*Phone: 0049 1788275671

Fax: 0049 30187542390

E-mail: Domingo-CarrascoC@rki.de

[†] Published ahead of print on 24 November 2010.